By sonia ziouani ammor In Kinesys News Tagged CTCL, Drug Development, Early Access, Early dialogue, MHRA, Oncology, Orphan Drug, Patient Access, PIM, Real-World Evidence, regulatory affairs
Kinesys Consulting last month secured another PIM designation, this time for a new oncology product, on behalf of a US partner. The product, successfully designated as a Promising Innovative Medicine (PIM) by the Medicines and Healthcare Products Regulatory Agency (MHRA), is being developed for the treatment of
Kinesys Consulting has secured its first PIM designation, for a novel oncology supportive care product, on behalf of a US partner. The product, designated as a Promising Innovative Medicine (PIM) by the Medicines and Healthcare Products Regulatory Agency (MHRA), is being developed for
By sonia ziouani ammor In Events Tagged Adcetris, ALXN1210, ASH, CAR-T cell, Clinical Trials, Crizanlizumab, CTL019, Glasdegib, Hematology, Highlights, IASLC, Ibrutinib, KTE-C19, Lenalidomide, Obinutuzumab, Oncology, SABCS, WCLC
ASH 2016 Highlights, December 3-6 2016AbbVie Inc. & Janssen – Ibrutinib (IMBRUVICA®). PCYC-1121-CA Phase II trial assessed ibrutinib as a single-agent treatment for marginal zone lymphoma patients that received one or more prior therapies including at least one CD20-directed regimen. In the study, 79% of
